Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
02/2003
02/13/2003WO2003012145A1 Antisense modulation of dual specific phosphatase 8 expression
02/13/2003WO2003012144A1 Antisense modulation of acyl coenzyme a cholesterol acyltransferase-1 expression
02/13/2003WO2003012141A1 Method of screening alzheimer’s disease-associated gene
02/13/2003WO2003012133A2 Isp-1 and ctb-1 genes and uses thereof
02/13/2003WO2003012127A2 Assay for identifying inhibitors of hiv rt dimerization
02/13/2003WO2003012123A2 Antisense modulation of dual specific phosphatase 9 expression
02/13/2003WO2003012122A2 Crystallized structure of type iv collagen nc1 domain hexamer
02/13/2003WO2003012112A1 Methylation resistant vectors
02/13/2003WO2003012111A2 Conjugates for the modulation of immune responses
02/13/2003WO2003012107A1 Hepatitis b virus pre-s1 derived synthetic polypeptides and uses thereof
02/13/2003WO2003012105A2 Vegf isoform
02/13/2003WO2003012103A2 Nucleic acids coding for novel fbox proteins, their diagnostic and therapeutic uses
02/13/2003WO2003012093A2 Regulator of calcineurin
02/13/2003WO2003012089A2 Crystal structure of beta-site app cleaving enzyme (bace) and use thereof
02/13/2003WO2003012078A2 Dendritic cells and the uses thereof in screening cellular targets and potential drugs
02/13/2003WO2003012072A2 Monoclonal antibodies to activated erbb family members and methods of use thereof
02/13/2003WO2003012065A2 Kinases and phosphatases
02/13/2003WO2003012063A2 Polynucleotide encoding a novel trp channel family member, ltrpc3, and splice variants thereof
02/13/2003WO2003012059A2 Antisense modulation of cyclin d2 expression
02/13/2003WO2003012057A2 Antisense modulation of serum amyloid a4 expression
02/13/2003WO2003012055A2 Sak: modulation of cellular proliferation for treatment of cancer
02/13/2003WO2003012052A2 Specific inhibition of gene expression by small double stranded rnas
02/13/2003WO2003012049A2 Methods and composition concerning herpes virus us3 and bad-involved apoptosis
02/13/2003WO2003012048A2 Antigens of and antibodies to translocated molecules of microorganisms and uses thereof
02/13/2003WO2003012045A2 Hybrid proteins with neuregulin heparin-binding domain for targeting to heparan sulfate proteoglycans
02/13/2003WO2003012044A2 Hagfish cathelin-associated antimicrobial peptides and genes
02/13/2003WO2003012043A2 Enhancing organ maturity in neonates and predicting their duration of intensive care
02/13/2003WO2003012035A2 Commercial use of arabidopsis for production of human and animal therapeutic and diagnostic proteins
02/13/2003WO2003012034A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
02/13/2003WO2003012033A2 Antisense modulation of short heterodimer partner-1 expression
02/13/2003WO2003012032A2 Antisense modulation of p70 s6 kinase expression
02/13/2003WO2003012031A2 Antisense modulation of stearoyl-coa desaturase expression
02/13/2003WO2003012030A2 Isoform-selective inhibitors and activators of pde3 cyclic
02/13/2003WO2003011908A2 Mutant forms of the tgf-b type ii receptor which bind all tgf-b isoforms and the use thereof
02/13/2003WO2003011907A2 Receptor, the use thereof, and mouse antibodies
02/13/2003WO2003011905A1 Novel serine protease
02/13/2003WO2003011903A2 Identification of specific tumor antigens by means of the selection of cdna libraries with sera
02/13/2003WO2003011902A1 Identification of specific tumour antigens by selection of cdna libraries with sera
02/13/2003WO2003011901A1 Methods for identifying substances interacting with pleckstrin homology domains, and proteins containing mutated pleckstrin homology domains
02/13/2003WO2003011898A2 Synthetic or natural peptides binding protein phosphatase 2a, identification method and uses
02/13/2003WO2003011896A1 Peptides having antiangiogenic activity
02/13/2003WO2003011895A2 Compositions and methods for modulation of immune responses
02/13/2003WO2003011893A2 Immunologically significant herpes simplex virus antigens and methods for using same
02/13/2003WO2003011892A2 Glp-1 exendin-4 peptide analogs and uses thereof
02/13/2003WO2003011890A1 Antisense modulation of corest expression
02/13/2003WO2003011889A2 Antisense modulation of acyl coa cholesterol acyltransferase-2 expression
02/13/2003WO2003011888A1 Antisense modulation of sap-1 expression
02/13/2003WO2003011887A2 Antisense modulation of apolipoprotein b expression
02/13/2003WO2003011878A2 Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
02/13/2003WO2003011842A1 Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
02/13/2003WO2003011823A2 Crfr1 selective ligands
02/13/2003WO2003011395A2 Method of utilizing neurotrophins to manipulate reproductive capacity
02/13/2003WO2003011369A1 Device for and method of controlled enzymatic removal and retrieval of tissue
02/13/2003WO2003011334A1 Vaccine comprising gp120 and nef and/or tat for the immunisation against hiv
02/13/2003WO2003011333A1 Botulinum toxin in the treatment or prevention of acne
02/13/2003WO2003011328A1 Pregnancy-related enzyme activity
02/13/2003WO2003011327A2 Secretin for the treatment of asthma
02/13/2003WO2003011326A1 Use of long pentraxin ptx3 for treating female infertility
02/13/2003WO2003011325A1 Agonists and antagonists of moceptin for the treatment of metabolic disorders
02/13/2003WO2003011324A1 Agonists and antagonists of moxifin for the treatment of metabolic disorders
02/13/2003WO2003011323A1 Agonists and antagonists of contabix for use in the treatment of metabolic disorders
02/13/2003WO2003011322A1 Agonists and antagonists of genoxin for use in the treatment of metabolic disorders
02/13/2003WO2003011321A1 Agonists and antagonists of cobesin for the treatment of metabolic disorders
02/13/2003WO2003011320A1 Agonists and antagonists of obesingen for the treatment of metabolic disorders
02/13/2003WO2003011319A1 Xobesin agonists and antagonists for the treatment of metabolic disorders
02/13/2003WO2003011318A1 Agonists and antagonists of famoset for use in the treatment of metabolic disorders
02/13/2003WO2003011317A1 Modulators of notch signalling for use in immunotherapy
02/13/2003WO2003011316A1 Combination of selective cox-2 inhibitor and lung surfactant for respiratory syndrome
02/13/2003WO2003011315A1 Composition for inhibiting tyrosine kinase activity of src proteins
02/13/2003WO2003011314A2 Use of lhrh-antagonists for the improvement of t-cell mediated immunity
02/13/2003WO2003011313A1 Osteogenic growth oligopeptides as stimulants of hematopoiesis
02/13/2003WO2003011304A1 Modulation of insulin-regulated aminopeptidase (irap)/angiotensin iv (at4) receptor activity
02/13/2003WO2003011300A1 As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness
02/13/2003WO2003011277A2 Methods to mobilize progenitor/stem cells
02/13/2003WO2003011261A1 Cyanoacrylate monomer-containing antibiotic formulation for topical use
02/13/2003WO2003011260A1 Method for the continuous production and coating of self-adhesive compounds on the basis of sbc that includes at least one pharmaceutically active substance
02/13/2003WO2003011251A1 Pulmonary formulation
02/13/2003WO2003011229A2 Durable multi-component antibiotic formulation for topical use
02/13/2003WO2003011213A2 Method for treating diabetes and obesity
02/13/2003WO2003011211A2 Peg-modified uricase
02/13/2003WO2003011118A2 Human zona pellucida proteins and methods of their use in diagnosing male infertility
02/13/2003WO2003011117A2 Methods and compositions for treating and preventing distal bowel lesions
02/13/2003WO2003011055A1 Nutritional composition preventing bacterial overgrowth
02/13/2003WO2003004595A9 Materials and methods relating to protein and nucleic acid evolution
02/13/2003WO2002099092A8 Production of recombinant human lysosomal alpha-mannosidase
02/13/2003WO2002098455A8 Production of recombinant human arylsulfatase a
02/13/2003WO2002096947A8 The lectin-like domain of thrombomodulin and its therapeutic use
02/13/2003WO2002089730A3 Compounds and methods for the modulation of cd154
02/13/2003WO2002083728A3 Splice variant
02/13/2003WO2002080849A3 Chemotherapeutic induction of egr-1 promoter activity
02/13/2003WO2002079380A3 Disruptions in gaba receptor rh02 subunit, methods adn uses thereof
02/13/2003WO2002072032A3 Compounds and methods for identifying, staging and treating cutaneous t-cell lymphoma
02/13/2003WO2002072016A3 Method of preventing adhesions with ifn-¿y?
02/13/2003WO2002069907A3 Anti-neovasculature preparations for cancer
02/13/2003WO2002069232A3 Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
02/13/2003WO2002066514A3 Artificial fusion proteins with reduced immunogenicity
02/13/2003WO2002066067A3 Albumin-based drug delivery system and antimicrobial peptides
02/13/2003WO2002065992A3 A cell therapy method for the treatment of tumors
02/13/2003WO2002062849A3 Isolated human ras-like proteins, nucleic acid molecules encoding them, and uses thereof
02/13/2003WO2002062810A3 Linkable sialyl lewis x analogs
1 ... 1904 1905 1906 1907 1908 1909 1910 1911 1912 1913 1914 1915 1916 1917 1918 1919 1920 1921 1922 1923 1924 ... 3163